{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:37:42Z","timestamp":1792237062302,"version":"4.4.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13318-025-00934-7","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:47:43Z","timestamp":1739357263000},"page":"105-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Critical Care Pharmacology of Antiretroviral Therapy in Adults"],"prefix":"10.1007","volume":"50","author":[{"given":"Luigi","family":"La Via","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cuttone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Nunnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Deana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Tesauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Voza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Planinsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslava","family":"Longhitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5764-6118","authenticated-orcid":false,"given":"Christian","family":"Zanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"9903","key":"934_CR1","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","volume":"382","author":"SG Deeks","year":"2013","unstructured":"Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525\u201333.","journal-title":"Lancet"},{"key":"934_CR2","doi-asserted-by":"crossref","unstructured":"Marino A, Pavone G, Martorana F, Fisicaro V, Motta L, Spampinato S, et al. Navigating the Nexus: HIV and Breast Cancer-A Critical Review. 2024 Mar 12;25(6).","DOI":"10.3390\/ijms25063222"},{"key":"934_CR3","doi-asserted-by":"crossref","unstructured":"Akg\u00fcn KM, Pisani M, Crothers K. The changing epidemiology of HIV-infected patients in the intensive care unit. Journal of intensive care medicine. 2011 May-Jun;26(3):151-64.","DOI":"10.1177\/0885066610387996"},{"key":"934_CR4","doi-asserted-by":"crossref","unstructured":"Pavone G, Marino A, Fisicaro V, Motta L, Spata A, Martorana F, et al. Entangled Connections: HIV and HPV Interplay in Cervical Cancer-A Comprehensive Review. International journal of molecular sciences. 2024 Sep 26;25(19).","DOI":"10.3390\/ijms251910358"},{"key":"934_CR5","doi-asserted-by":"crossref","unstructured":"Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Critical care clinics. 2006 Apr;22(2):255-71, vi.","DOI":"10.1016\/j.ccc.2006.02.011"},{"issue":"2","key":"934_CR6","first-page":"125","volume":"65","author":"A Tseng","year":"2012","unstructured":"Tseng A, Foisy M, Hughes CA, Kelly D, Chan S, Dayneka N, et al. Role of the pharmacist in caring for patients with HIV\/AIDS: clinical practice guidelines. Can J Hosp Pharm. 2012;65(2):125\u201345.","journal-title":"Can J Hosp Pharm"},{"issue":"3","key":"934_CR7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.annemergmed.2008.01.324","volume":"52","author":"A Venkat","year":"2008","unstructured":"Venkat A, Piontkowsky DM, Cooney RR, Srivastava AK, Suares GA, Heidelberger CP. Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy. Ann Emerg Med. 2008;52(3):274\u201385.","journal-title":"Ann Emerg Med"},{"issue":"9377","key":"934_CR8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","volume":"362","author":"A Mocroft","year":"2003","unstructured":"Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d\u2019Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22\u20139.","journal-title":"Lancet"},{"key":"934_CR9","doi-asserted-by":"crossref","unstructured":"Gulick RM. Antiretroviral treatment 2010: progress and controversies. Journal of acquired immune deficiency syndromes (1999). 2010;55 Suppl 1(Suppl 1):S43-8.","DOI":"10.1097\/QAI.0b013e3181f9c09e"},{"key":"934_CR10","doi-asserted-by":"crossref","unstructured":"Greene M, Covinsky KE, Valcour V, Miao Y, Madamba J, Lampiris H, et al. Geriatric Syndromes in Older HIV-Infected Adults. Journal of acquired immune deficiency syndromes (1999). 2015 Jun 1;69(2):161-7.","DOI":"10.1097\/QAI.0000000000000556"},{"key":"934_CR11","doi-asserted-by":"crossref","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Critical care medicine. 2009 Mar;37(3):840-51; quiz 59.","DOI":"10.1097\/CCM.0b013e3181961bff"},{"issue":"6","key":"934_CR12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/08971900211000692","volume":"35","author":"CK Walker","year":"2022","unstructured":"Walker CK, Shaw CM, Moss Perry MV, Claborn MK. Antiretroviral Therapy Management in Adults With HIV During ICU Admission. J Pharm Pract. 2022;35(6):952\u201362.","journal-title":"J Pharm Pract"},{"key":"934_CR13","doi-asserted-by":"crossref","unstructured":"Song IH, Zong J, Borland J, Jerva F, Wynne B, Zamek-Gliszczynski MJ, et al. The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects. Journal of acquired immune deficiency syndromes (1999). 2016;72(4):400-7.","DOI":"10.1097\/QAI.0000000000000983"},{"issue":"5","key":"934_CR14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archinte.163.5.601","volume":"163","author":"E Lautenbach","year":"2003","unstructured":"Lautenbach E, Larosa LA, Kasbekar N, Peng HP, Maniglia RJ, Fishman NO. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med. 2003;163(5):601\u20135.","journal-title":"Arch Intern Med"},{"issue":"6","key":"934_CR15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498\u2013509.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"934_CR16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/088922203769232629","volume":"19","author":"M Boffito","year":"2003","unstructured":"Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19(9):825\u201335.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"934_CR17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/00003088-200544100-00002","volume":"44","author":"F Pea","year":"2005","unstructured":"Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44(10):1009\u201334.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"934_CR18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"ET Morgan","year":"2009","unstructured":"Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"934_CR19","doi-asserted-by":"crossref","unstructured":"De Sousa Mendes M, Chetty M. Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. 2019 Dec;19(4):339-50","DOI":"10.1007\/s40268-019-00285-0"},{"key":"934_CR20","doi-asserted-by":"crossref","unstructured":"Pilkington V, Hughes SL, Pepperrell T, McCann K, Gotham D, Pozniak AL, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14\u200a894 patients across 14 trials. AIDS (London, England). 2020 Dec 1;34(15):2259-68.","DOI":"10.1097\/QAD.0000000000002699"},{"issue":"5","key":"934_CR21","first-page":"846","volume":"16","author":"MS Patern\u00f2 Raddusa","year":"2024","unstructured":"Patern\u00f2 Raddusa MS, Marino A, Celesia BM, Spampinato S, Giarratana C, Venanzi Rullo E, et al. Atherosclerosis and cardiovascular complications in people living with HIV. A Focused Rev. 2024;16(5):846\u201363.","journal-title":"A Focused Rev."},{"issue":"8","key":"934_CR22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/apt.16854","volume":"55","author":"A Hill","year":"2022","unstructured":"Hill A. Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Aliment Pharmacol Ther. 2022;55(8):1042\u20133.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"934_CR23","first-page":"1","volume":"49","author":"AA Udy","year":"2010","unstructured":"Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Drugs R&D. 2010;49(1):1\u201316.","journal-title":"Drugs R&D"},{"issue":"7","key":"934_CR24","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1097\/CCM.0b013e3181aab3d0","volume":"37","author":"G Choi","year":"2009","unstructured":"Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37(7):2268\u201382.","journal-title":"Crit Care Med"},{"issue":"3","key":"934_CR25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FTD.0b013e31821b42d1","volume":"33","author":"E Pretorius","year":"2011","unstructured":"Pretorius E, Klinker H, Rosenkranz B. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther Drug Monit. 2011;33(3):265\u201374.","journal-title":"Ther Drug Monit"},{"key":"934_CR26","doi-asserted-by":"crossref","unstructured":"Wen H, Yin L, Wang J, Zhang L, Sun T, Xu F, et al. Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function. 2022;15(5):647-55","DOI":"10.1080\/17512433.2022.2078306"},{"issue":"1","key":"934_CR27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/QCO.0000000000000026","volume":"27","author":"NM Archin","year":"2014","unstructured":"Archin NM, Margolis DM. Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis. 2014;27(1):29\u201335.","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"934_CR28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/viru.26516","volume":"5","author":"JS Boomer","year":"2014","unstructured":"Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence. 2014;5(1):45\u201356.","journal-title":"Virulence."},{"key":"934_CR29","doi-asserted-by":"crossref","unstructured":"Barreto-de-Souza V, Arakelyan A, Margolis L, Vanpouille C. HIV-1 vaginal transmission: cell-free or cell-associated virus? American journal of reproductive immunology (New York, NY : 1989). 2014;71(6):589-99.","DOI":"10.1111\/aji.12240"},{"key":"934_CR30","doi-asserted-by":"crossref","unstructured":"Lavalle S, Masiello E, Iannella G, Magliulo G, Pace A, Lechien J, et al. Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review. 2024;14(4).","DOI":"10.3390\/life14040425"},{"issue":"9","key":"934_CR31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2174\/138161206776055787","volume":"12","author":"JC Slish","year":"2006","unstructured":"Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, et al. Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. Curr Pharm Des. 2006;12(9):1129\u201345.","journal-title":"Curr Pharm Des"},{"issue":"10","key":"934_CR32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2009.142","volume":"5","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5(10):563\u201373.","journal-title":"Nat Rev Nephrol"},{"key":"934_CR33","doi-asserted-by":"crossref","unstructured":"Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clinical pharmacokinetics. 1998;35(4):275-91.","DOI":"10.2165\/00003088-199835040-00002"},{"key":"934_CR34","doi-asserted-by":"crossref","unstructured":"Marino A, Zafarana G, Ceccarelli M, Cosentino F, Moscatt V, Bruno G, et al. Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV\/HCV Coinfected Patients: Monocentric Italian Experience. 2021;11(12).","DOI":"10.3390\/diagnostics11122336"},{"key":"934_CR35","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3389\/fimmu.2017.01461","volume":"8","author":"AJ Theron","year":"2017","unstructured":"Theron AJ, Anderson R, Rossouw TM, Steel HC. The role of transforming growth factor beta-1 in the progression of HIV\/AIDS and development of non-AIDS-defining fibrotic disorders. Front Immunol. 2017;8:1461.","journal-title":"Front Immunol"},{"issue":"1","key":"934_CR36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3934\/microbiol.2023002","volume":"9","author":"MI Zapata-Cardona","year":"2023","unstructured":"Zapata-Cardona MI, Florez-Alvarez L, Guerra-Sandoval AL, Chvatal-Medina M, Guerra-Almonacid CM, Hincapie-Garcia J, et al. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: a drug repurposing approach. AIMS microbiology. 2023;9(1):20\u201340.","journal-title":"AIMS microbiology."},{"issue":"8","key":"934_CR37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-200363080-00002","volume":"63","author":"RE Aarnoutse","year":"2003","unstructured":"Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs. 2003;63(8):741\u201353.","journal-title":"Drugs"},{"issue":"21","key":"934_CR38","volume":"26","author":"BM Celesia","year":"2020","unstructured":"Celesia BM, Marino A, Borracino S, Arcadipane AF, Pant\u00f2 G, Gussio M, et al. Successful extracorporeal membrane oxygenation treatment in an acquired immune deficiency syndrome (AIDS) patient with acute respiratory distress syndrome (ARDS) complicating Pneumocystis jirovecii pneumonia: a challenging case. The American journal of case reports. 2020;26(21): e919570.","journal-title":"The American journal of case reports."},{"issue":"6","key":"934_CR39","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/jcm13061634.PMID:38541861;PMCID:PMC10971170","volume":"13","author":"T Romenskaya","year":"2024","unstructured":"Romenskaya T, Longhitano Y, Mahajan A, Savioli G, Voza A, Tesauro M, Zanza C. Extra-corporeal membrane oxygenation in pregnancy. J Clin Med. 2024;13(6):1634. https:\/\/doi.org\/10.3390\/jcm13061634.PMID:38541861;PMCID:PMC10971170.","journal-title":"J Clin Med"},{"issue":"3","key":"934_CR40","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.23716","volume":"52","author":"M N\u00fa\u00f1ez","year":"2010","unstructured":"N\u00fa\u00f1ez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology (Baltimore, MD). 2010;52(3):1143\u201355.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"934_CR41","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.201006-0836OC","volume":"183","author":"K Crothers","year":"2011","unstructured":"Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388\u201395.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"934_CR42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneurol.2007.31","volume":"65","author":"S Letendre","year":"2008","unstructured":"Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65\u201370.","journal-title":"Arch Neurol"},{"issue":"2","key":"934_CR43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1212\/WNL.0000000000000564","volume":"83","author":"EC Caniglia","year":"2014","unstructured":"Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 2014;83(2):134\u201341.","journal-title":"Neurology"},{"issue":"26","key":"934_CR44","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","volume":"370","author":"DR Boulware","year":"2014","unstructured":"Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"1","key":"934_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2014.09.001","volume":"19","author":"C Acharya","year":"2015","unstructured":"Acharya C, Dharel N, Sterling RK. Chronic liver disease in the human immunodeficiency virus patient. Clin Liver Dis. 2015;19(1):1\u201322.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"934_CR46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/phar.1882","volume":"37","author":"MA Ha","year":"2017","unstructured":"Ha MA, Sieg AC. Evaluation of altered drug pharmacokinetics in critically Ill adults receiving extracorporeal membrane oxygenation. Pharmacotherapy. 2017;37(2):221\u201335.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"934_CR47","first-page":"312","volume":"19","author":"S Mousavi","year":"2011","unstructured":"Mousavi S, Levcovich B, Mojtahedzadeh M. A systematic review on pharmacokinetic changes in critically ill patients: role of extracorporeal membrane oxygenation. Daru. 2011;19(5):312\u201321.","journal-title":"Daru"},{"issue":"1","key":"934_CR48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13054-015-0753-8","volume":"19","author":"TH Kiser","year":"2015","unstructured":"Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, et al. Evaluation of sulfobutylether-\u03b2-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Critical care (London, England). 2015;19(1):32.","journal-title":"Critical care (London, England)."},{"key":"934_CR49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fphar.2014.00065","volume":"5","author":"MM Costantine","year":"2014","unstructured":"Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:65.","journal-title":"Front Pharmacol"},{"issue":"10","key":"934_CR50","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","volume":"379","author":"R Zash","year":"2018","unstructured":"Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018;379(10):979\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"934_CR51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107009","volume":"63","author":"AM Hitchcock","year":"2024","unstructured":"Hitchcock AM, Kufel WD, Dwyer KAM, Sidman EF. Lenacapavir: A novel injectable HIV-1 capsid inhibitor. Int J Antimicrob Agents. 2024;63(1): 107009.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"934_CR52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/COH.0000000000000712","volume":"17","author":"PM Grant","year":"2022","unstructured":"Grant PM, Kozal MJ. Fostemsavir: a first-in-class HIV-1 attachment inhibitor. Curr Opin HIV AIDS. 2022;17(1):32\u20135.","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"934_CR53","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","volume":"379","author":"B Emu","year":"2018","unstructured":"Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018;379(7):645\u201354.","journal-title":"N Engl J Med"},{"issue":"3","key":"934_CR54","first-page":"456","volume":"5","author":"L La Via","year":"2024","unstructured":"La Via L, Sangiorgio G, Stefani S, Marino A, Nunnari G, Cocuzza S, et al. The Global Burden of Sepsis and Septic Shock. 2024;5(3):456\u201378.","journal-title":"The Global Burden of Sepsis and Septic Shock."},{"issue":"8","key":"934_CR55","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s40262-024-01397-w","volume":"63","author":"F Ferrari","year":"2024","unstructured":"Ferrari F, Milla P, Sartori M, Zanza C, Tesauro M, Longhitano Y, De Silvestri A, Abbruzzese C, De Rosa S, Lassola S, Samoni S, Brendolan A, Zanella M, Scaravilli V, Grasselli G, Arpicco S, Ronco C. Antibiotics Removal during Continuous Renal Replacement Therapy in Septic Shock Patients: Mixed Modality Versus \u201cExpanded Haemodialysis.\u201d Clin Pharmacokinet. 2024;63(8):1167\u201376. https:\/\/doi.org\/10.1007\/s40262-024-01397-w. (Epub 2024 Aug 5 PMID: 39102092).","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"934_CR56","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/17512433.2016.1235972","volume":"9","author":"B Punyawudho","year":"2016","unstructured":"Punyawudho B, Singkham N, Thammajaruk N, Dalodom T, Kerr SJ, Burger DM, et al. Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients. Expert Rev Clin Pharmacol. 2016;9(12):1583\u201395.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"934_CR57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijantimicag.2010.02.017","volume":"36","author":"O Burkhardt","year":"2010","unstructured":"Burkhardt O, Thon S, Burhenne J, Welte T, Kielstein JT. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Int J Antimicrob Agents. 2010;36(1):93\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"934_CR58","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200203001-00002","volume":"16","author":"D Back","year":"2002","unstructured":"Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS (London, England). 2002;16(Suppl 1):S5-37.","journal-title":"AIDS (London, England)."},{"issue":"18","key":"934_CR59","first-page":"2391","volume":"18","author":"DW Haas","year":"2004","unstructured":"Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (London, England). 2004;18(18):2391\u2013400.","journal-title":"AIDS (London, England)."},{"issue":"2","key":"934_CR60","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkr498","volume":"67","author":"D Cattaneo","year":"2012","unstructured":"Cattaneo D, Gervasoni C, Meraviglia P, Landonio S, Fucile S, Cozzi V, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother. 2012;67(2):460\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"934_CR61","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/FTD.0000000000000684","volume":"42","author":"D Cattaneo","year":"2020","unstructured":"Cattaneo D, Baldelli S, Cozzi V, Clementi E, Marriott DJE, Gervasoni C. impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of people living with HIV: a narrative review. Ther Drug Monit. 2020;42(1):64\u201374.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"934_CR62","first-page":"117","volume":"27","author":"JG Gerber","year":"2003","unstructured":"Gerber JG, Acosta EP. Therapeutic drug monitoring in the treatment of HIV-infection. J Clin. 2003;27(2):117\u201328.","journal-title":"J Clin"},{"issue":"1","key":"934_CR63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","volume":"283","author":"MS Sulkowski","year":"2000","unstructured":"Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74\u201380.","journal-title":"JAMA"},{"key":"934_CR64","unstructured":"D\u2019Andrea F. VRE, Marino A., Moscatt V., Celesia B. M., Cacopardo B., Condorelli F., La Rocca G., Di Rosa M., Pellican\u00f2 G. F., Nunnari G., Ceccarelli M. Hepatitis B virus infection and hepatocellular carcinoma in PLWH: epidemiology, pathogenesis and treatment. World Cancer Research Journal. 2020(7)."},{"issue":"7","key":"934_CR65","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340-52.e7.","journal-title":"Gastroenterology"},{"issue":"5","key":"934_CR66","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496\u2013505.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"934_CR67","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","volume":"24","author":"A Mocroft","year":"2010","unstructured":"Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (London, England). 2010;24(11):1667\u201378.","journal-title":"AIDS (London, England)."},{"issue":"21","key":"934_CR68","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","volume":"349","author":"N Friis-M\u00f8ller","year":"2003","unstructured":"Friis-M\u00f8ller N, Sabin CA, Weber R, d\u2019Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993\u20132003.","journal-title":"N Engl J Med"},{"issue":"11","key":"934_CR69","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3390\/biology11111626.PMID:36358327;PMCID:PMC9687154","volume":"11","author":"C Zanza","year":"2022","unstructured":"Zanza C, Caputo G, Tornatore G, Romenskaya T, Piccioni A, Franceschi F, Artico M, Taurone S, Savioli G, Longhitano Y. Cellular immuno-profile in septic human host: a scoping review. Biology (Basel). 2022;11(11):1626. https:\/\/doi.org\/10.3390\/biology11111626.PMID:36358327;PMCID:PMC9687154.","journal-title":"Biology (Basel)."},{"issue":"4","key":"934_CR70","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0091270003251864","volume":"43","author":"DJ Greenblatt","year":"2003","unstructured":"Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol. 2003;43(4):414\u201322.","journal-title":"J Clin Pharmacol"},{"key":"934_CR71","doi-asserted-by":"crossref","unstructured":"Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS (London, England). 1998;12(14):1735-44.","DOI":"10.1097\/00002030-199814000-00004"},{"key":"934_CR72","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","volume":"46","author":"DS Clutter","year":"2016","unstructured":"Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292\u2013307.","journal-title":"Infect Genet Evol"},{"issue":"4","key":"934_CR73","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2174\/1574887115666200811105251","volume":"15","author":"Y Longhitano","year":"2020","unstructured":"Longhitano Y, Zanza C, Thangathurai D, Taurone S, Kozel D, Racca F, Audo A, Ravera E, Migneco A, Piccioni A, Franceschi F. Gut alterations in septic patients: a biochemical literature review. Rev Recent Clin Trials. 2020;15(4):289\u201397. https:\/\/doi.org\/10.2174\/1574887115666200811105251. (PMID: 32781963).","journal-title":"Rev Recent Clin Trials"},{"key":"934_CR74","doi-asserted-by":"crossref","unstructured":"Ambrosioni J, Levi L, Alagaratnam J. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. 2023;24(11):1126-36.","DOI":"10.1111\/hiv.13542"},{"issue":"1","key":"934_CR75","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.antiviral.2009.09.015","volume":"85","author":"R Paredes","year":"2010","unstructured":"Paredes R, Clotet B. Clinical management of HIV-1 resistance. Antiviral Res. 2010;85(1):245\u201365.","journal-title":"Antiviral Res"},{"issue":"1","key":"934_CR76","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","volume":"31","author":"SY Rhee","year":"2003","unstructured":"Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31(1):298\u2013303.","journal-title":"Nucleic Acids Res"},{"issue":"22","key":"934_CR77","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","volume":"355","author":"WM El-Sadr","year":"2006","unstructured":"El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"934_CR78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005575","volume":"4","author":"A Zolopa","year":"2009","unstructured":"Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE. 2009;4(5): e5575.","journal-title":"PLoS ONE"},{"issue":"4","key":"934_CR79","first-page":"132","volume":"24","author":"AM Wensing","year":"2016","unstructured":"Wensing AM, Calvez V, G\u00fcnthard HF, Johnson VA, Paredes R, Pillay D, et al. 2017 update of the drug resistance mutations in HIV-1. Top Antiviral Med. 2016;24(4):132\u20133.","journal-title":"Top Antiviral Med."},{"issue":"5","key":"934_CR80","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","volume":"11","author":"L Wittkop","year":"2011","unstructured":"Wittkop L, G\u00fcnthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363\u201371.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"934_CR81","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/fmb.11.121","volume":"6","author":"L B\u00e9lec","year":"2011","unstructured":"B\u00e9lec L, Bonn JP. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. Future Microbiol. 2011;6(11):1251\u201360.","journal-title":"Future Microbiol"},{"issue":"9","key":"934_CR82","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/ciu094","volume":"58","author":"H Masur","year":"2014","unstructured":"Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the centers for disease control and prevention, national institutes of health, and hiv medicine association of the infectious diseases society of America. Clinical Infect Dis. 2014;58(9):1308\u201311.","journal-title":"Clinical Infect Dis."},{"key":"934_CR83","doi-asserted-by":"crossref","unstructured":"Grant PM, Komarow L, Andersen J, Sereti I, Pahwa S, Lederman MM, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PloS one. 2010 Jul 1;5(7):e11416.","DOI":"10.1371\/journal.pone.0011416"},{"issue":"10167","key":"934_CR84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"P Cahn","year":"2019","unstructured":"Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"934_CR85","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"934_CR86","first-page":"111","volume":"27","author":"AM Wensing","year":"2019","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, G\u00fcnthard HF, Paredes R, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antiviral Med. 2019;27(3):111\u201321.","journal-title":"Top Antiviral Med."},{"issue":"1","key":"934_CR87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12981-016-0115-x","volume":"13","author":"J Jiang","year":"2016","unstructured":"Jiang J, Xu X, Guo W, Su J, Huang J, Liang B, et al. Dolutegravir(DTG, S\/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. AIDS Res Ther. 2016;13(1):30.","journal-title":"AIDS Res Ther"},{"issue":"9581","key":"934_CR88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0140-6736(07)61027-7","volume":"370","author":"A Calmy","year":"2007","unstructured":"Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet. 2007;370(9581):12\u20134.","journal-title":"Lancet"},{"issue":"20","key":"934_CR89","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1800762","volume":"379","author":"G Meintjes","year":"2018","unstructured":"Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, et al. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. N Engl J Med. 2018;379(20):1915\u201325.","journal-title":"N Engl J Med"},{"issue":"12","key":"934_CR90","first-page":"1112","volume":"382","author":"S Welch","year":"2020","unstructured":"Welch S, Koval A, Mendao L, Rockstroh JK, Swindells S, Andrade-Villanueva JF, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. HIV Med. 2020;382(12):1112\u201323.","journal-title":"HIV Med"},{"issue":"2","key":"934_CR91","first-page":"460","volume":"67","author":"D Cattaneo","year":"2012","unstructured":"Cattaneo D, Gervasoni C, Meraviglia P, Landonio S, Fucile S, Cozzi V, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. N Engl J Med. 2012;67(2):460\u20134.","journal-title":"N Engl J Med"},{"issue":"5","key":"934_CR92","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","volume":"101","author":"AS Darwich","year":"2017","unstructured":"Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, et al. Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101(5):646\u201356.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"934_CR93","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425247.2017.1288212","volume":"14","author":"B Edagwa","year":"2017","unstructured":"Edagwa B, McMillan J, Sillman B, Gendelman HE. Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv. 2017;14(11):1281\u201391.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"934_CR94","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1574887116666211118141117","volume":"17","author":"V Siciliano","year":"2022","unstructured":"Siciliano V, Ros\u00e0 T, Del Vecchio P, D\u2019Angelillo A, Brigida M, Longhitano Y, Zanza C, Santoro MC, Candelli M, Franceschi F, Piccioni A. Viral encephalitis in adults: a narrative review. Rev Recent Clin Trials. 2022;17(4):259\u201367. https:\/\/doi.org\/10.2174\/1574887116666211118141117. (PMID: 34792015).","journal-title":"Rev Recent Clin Trials"},{"issue":"7557","key":"934_CR95","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487\u201391.","journal-title":"Nature"},{"issue":"21","key":"934_CR96","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. 2016;375(21):2037\u201350.","journal-title":"N Engl J Med"},{"issue":"18","key":"934_CR97","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.2174\/0929867328666210915115056","volume":"29","author":"C Zanza","year":"2022","unstructured":"Zanza C, Romenskaya T, Thangathurai D, Ojetti V, Saviano A, Abenavoli L, et al. Microbiome in critical care: an unconventional and unknown ally. Curr Med Chem. 2022;29(18):3179\u201388.","journal-title":"Curr Med Chem"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00934-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T12:15:54Z","timestamp":1741176954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00934-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00934-7","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"6 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LLV, GC developed the concept and outline for the review; AM,GN, CZ wrote the first draft of the manuscript; YL, MT, RP edited the manuscript; CD searched the articles. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}